• ABOUT
    SUNHAWK VISION

Sunhawk Vision
In the early research stage, the team received generous financial and administrative supports from the Taiwan Ministry of Science and Technology to develop the proprietary technology and compounds to control myopia progression in pediatric subjects.
With the assistance from Taiwan Startup Institute, the team established Sunhawk Vision Biotech, Inc. in August 2019. The Company facilitated the translation of early R&D results to the final ophthalmic product and completed all pre-clinical studies. In 2021, the Company submitted first-in-human IND to US FDA, and it was approved without any comments/revisions. In Sept 2021, the first-in-human Phase-I Clinical Trial (NCT04928144) was completed, and the results showed no drug-related adverse effect, high tolerance by the pediatric study subjects and great therapeutic potential. The IND submission of the anti-myopia eye drop on February 2021 was approved by U.S. FDA with no comment.
It is expected that the investigative drug will successfully enter Phase 2 and Phase 3 trials and will enter the global market in next few years.

  • ABOUT
    DREAMHAWK VISION
    公司簡介

Dreamhawk Vision
Dreamhawk Vision Biotech, Inc. was established by same team of Sunhawk Vision Biotech in April 2021. The company focuses on the research and development of oligonucleotide drugs for ocular diseases based on the RNA therapy platform. Indications that are currently under development include dry eye disease and ocular surface diseases. The company team recently reported the excellent effect of our oligonucleotide drug in treating dry eye disease via novel mechanism of action including fast corneal repair, a reduction of corneal apoptosis, improvement of Meibomian gland and an increase of mucin secretion.
The company plans to launch a Phase-II clinical trial for dry eye disease in 2022 and more trials in 2023.

Our vision goal is to become the world’s most innovative and valuable ophthalmic new drug biotechnology company.

  • FOUNDER
    INTRODUCTION
The Chairman, Dr. Chung-Ling (Christine) Liang, received both her medical and PhD degrees from the Chang Gung University in Taiwan. She is a board-certified ophthalmologist in Taiwan. She was also trained in pediatric ophthalmology as her sub-specialty in the Massachusetts Eye and Ear Infirmary (MEEI)/Harvard Medical School. Dr. Liang served as a senior attending physician at Chang Gung Hospital and Department Chief at Kaohsiung Municipal Hospital. She is the founding Chair of Department of Ophthalmology at Asian University Hospital. She is an associate professor and currently is the Medical Director at Bright Eyes Clinics in Kaohsiung City, Taiwan.
  • Dr. Liang
Dr. Suh-Hang Hank Juo is the key inventor of the novel anti-myopia eye drops. He received MD degree from the Kaohsiung Medical University, MS degree from the Harvard University and PhD degree from the Johns Hopkins University. Dr. Suh-Hang Hank Juo finished his post-doc fellowships at Rockefeller University and National Institutes of Health (NIH) USA. He was appointed as an assistant professor and then associate professor at Columbia University. He is an internationally known human geneticist and a board-certified neurologist. He has published more than 180 peer-reviewed SCI papers with citation times more than 5800. He received many awards domestically and internationally. Currently, he is a distinguished professor at the China Medical University in Taiwan.
  • Dr. Hank Juo
  • AWARDS
Pharmaceutical Technology R&D Award
Future technology award
Public outreach award
Public outreach award
National innovation award
National innovation award
Future technology award
Outstanding research award
Outstanding research award
Future technology award
Break Out and Soar High Award
  • RESEARCH
  • Recommended myopia papers
    link to recommended research articles
    more
    +
  • Recommended dry eye papers
    link to recommended research articles
    more
    +